Close this search box.

Paper by Henri Meijering (Ardena) Kinetics of myelin breakdown products: A labeling study in patients with progressive multiple sclerosis

Henri Meijering (senior project manager at Ardena) recently co-authored a scientific article published by Clinical and Translational Science (March 2022) about Kinetics of myelin breakdown products: A labelling study in patients with progressive multiple sclerosis.

Multiple sclerosis (MS) affects millions of individuals worldwide and is the most common autoimmune disorder of the central nervous system (with estimated 2 million patients). Despite the fact that the disease has been known for more than 180 years, the exact pathophysiology of the disease is not clear. MS is primarily an inflammatory disorder of the brain and spinal cord in which focal lymphocytic infiltration leads to damage of myelin (demyelination) and axons. The majority of the available disease-modifying therapies for MS reduce inflammation. However, these therapies do not enhance remyelination and at best attenuate neuronal degeneration which will therefore still progress, leading to progressive disability in MS.

Development of compounds that stimulate remyelination is seen as an important target for drug development. Examples of such compounds are anti-LINGO antibodies, rHIgM22 antibodies, Olesoxime, and Quetiapine fumarate. The most direct way to demonstrate pharmacological effects of these compounds in future proof-of-concept studies is the quantification of myelin formation or remyelination.

Read the full news item of Ardena on the ASCPT website

Pivot Park Captains' Dinner

10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.

Now it’s time to celebrate!

We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.

Erwin Wurm | Am I a House?

For the first time, the artist shows a cross-section of his work, from Narrow Furniture to One Minute Sculptures, within the walls of a historic building. Villa Constance, a former home that today houses Museum Jan Cunen, is not only a location but also part of the conversation. Because what exactly is a house?


The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.

Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.

This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.

We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.

Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.